

PHH1289-50ug · 50ug
Verified Partner
Sign in to see pricing and request a quote.
Brand Store Product
No external links. Get your quote directly here.

Description
EnkiLife provides the Recombinant Human PDGFRB (C-6His) protein,aslo know as Platelet-Derived Growth Factor Receptor Beta,PDGF-R-Beta,PDGFR-Beta,Beta Platelet-Derived Growth Factor Receptor,Beta-Type Platelet-Derived Growth Factor Receptor,CD140 Antigen-Like Family Member B,Platelet-Derived Growth Factor Receptor 1,PDGFR-1,CD140b,PDGFRB,PDGFR,PDGFR1, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Platelet-Derived Growth Factor Receptor Beta is produced by our Mammalian expression system and the target gene encoding Leu33-Phe530 is expressed with a 6His tag at the C-terminus.Accession:AAH32224.1. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:57.17 KDa. Background:Platelet-Derived Growth Factor Receptor β (PDGFR-β) is a member of the protein kinase superfamily and CSF-1/PDGF receptor subfamily. The PDGF family consists of PDGF-A, -B, -C and -D, which form either homo- or heterodimers (PDGF-AA, -AB, -BB, -CC, -DD). The four PDGFs are inactive in their monomeric forms. The PDGFs bind to the protein tyrosine kinase receptors PDGF receptor-α and -β. These two receptor isoforms dimerize upon binding the PDGF dimer, leading to three possible receptor combinations, namely -αα, -ββ and -αβ. The extracellular region of the PDGF receptor-β consists of five immunoglobulin-like domains while the intracellular part is a tyrosine kinase domain. In addition to being a potent mitogen for cells of mesenchymal origin, PDGF has also been shown to be a potent chemoattractant for mesenchymal cells, mononuclear cells, and neutrophils and has been reported to be important in the modification of cellular matrix constituents.







